Type 2 Diabetes - Pipeline Review, H2 2017

Date: November 21, 2017
Pages: 1126
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: TBD9F1A0B80EN
Leaflet:

Download PDF Leaflet

Type 2 Diabetes - Pipeline Review, H2 2017
Type 2 Diabetes - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Pipeline Review, H2 2017, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.

Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 15, 2, 23, 66, 68, 3, 234, 77 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 68 and 20 molecules, respectively.

Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Type 2 Diabetes - Overview
Type 2 Diabetes - Therapeutics Development
Type 2 Diabetes - Therapeutics Assessment
Type 2 Diabetes - Companies Involved in Therapeutics Development
Type 2 Diabetes - Drug Profiles
Type 2 Diabetes - Dormant Projects 1018
Type 2 Diabetes - Discontinued Products 1050
Type 2 Diabetes - Product Development Milestones 1060
Appendix 1070

LIST OF TABLES

Number of Products under Development for Type 2 Diabetes, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..11), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..12), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..13), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..14), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Products under Development by Companies, H2 2017 (Contd..8), H2 2017
Products under Development by Companies, H2 2017 (Contd..9), H2 2017
Products under Development by Companies, H2 2017 (Contd..10), H2 2017
Products under Development by Companies, H2 2017 (Contd..11), H2 2017
Products under Development by Companies, H2 2017 (Contd..12), H2 2017
Products under Development by Companies, H2 2017 (Contd..13), H2 2017
Products under Development by Companies, H2 2017 (Contd..14), H2 2017
Products under Development by Companies, H2 2017 (Contd..15), H2 2017
Products under Development by Companies, H2 2017 (Contd..16), H2 2017
Products under Development by Companies, H2 2017 (Contd..17), H2 2017
Products under Development by Companies, H2 2017 (Contd..18), H2 2017
Products under Development by Companies, H2 2017 (Contd..19), H2 2017
Products under Development by Companies, H2 2017 (Contd..20), H2 2017
Products under Development by Companies, H2 2017 (Contd..21), H2 2017
Products under Development by Companies, H2 2017 (Contd..22), H2 2017
Products under Development by Companies, H2 2017 (Contd..23), H2 2017
Products under Development by Companies, H2 2017 (Contd..24), H2 2017
Products under Development by Companies, H2 2017 (Contd..25), H2 2017
Products under Development by Companies, H2 2017 (Contd..26), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Type 2 Diabetes - Pipeline by 4P Therapeutics LLC, H2 2017
Type 2 Diabetes - Pipeline by Addex Therapeutics Ltd, H2 2017
Type 2 Diabetes - Pipeline by Adocia SAS, H2 2017
Type 2 Diabetes - Pipeline by Aegis Therapeutics LLC, H2 2017
Type 2 Diabetes - Pipeline by AFFiRiS AG, H2 2017
Type 2 Diabetes - Pipeline by Allergan Plc, H2 2017
Type 2 Diabetes - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017
Type 2 Diabetes - Pipeline by Amgen Inc, H2 2017
Type 2 Diabetes - Pipeline by AntriaBio Inc, H2 2017
Type 2 Diabetes - Pipeline by Aphios Corp, H2 2017
Type 2 Diabetes - Pipeline by Araim Pharmaceuticals Inc, H2 2017
Type 2 Diabetes - Pipeline by Arecor Ltd, H2 2017
Type 2 Diabetes - Pipeline by Arena Pharmaceuticals Inc, H2 2017
Type 2 Diabetes - Pipeline by Astellas Pharma Inc, H2 2017
Type 2 Diabetes - Pipeline by AstraZeneca Plc, H2 2017
Type 2 Diabetes - Pipeline by AusBio Ltd, H2 2017
Type 2 Diabetes - Pipeline by Avadel Pharmaceuticals Plc, H2 2017
Type 2 Diabetes - Pipeline by Bayer AG, H2 2017
Type 2 Diabetes - Pipeline by Betagenon AB, H2 2017
Type 2 Diabetes - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Biocon Ltd, H2 2017
Type 2 Diabetes - Pipeline by BioLingus AG, H2 2017
Type 2 Diabetes - Pipeline by BioRestorative Therapies Inc, H2 2017
Type 2 Diabetes - Pipeline by Biozeus, H2 2017
Type 2 Diabetes - Pipeline by Biscayne Pharmaceuticals Inc, H2 2017
Type 2 Diabetes - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Type 2 Diabetes - Pipeline by Boston Therapeutics Inc, H2 2017
Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H2 2017
Type 2 Diabetes - Pipeline by Bristol-Myers Squibb Co, H2 2017
Type 2 Diabetes - Pipeline by C4X Discovery Holdings PLC, H2 2017
Type 2 Diabetes - Pipeline by Cadila Healthcare Ltd, H2 2017
Type 2 Diabetes - Pipeline by Cadila Pharmaceuticals Ltd, H2 2017
Type 2 Diabetes - Pipeline by Caelus Health, H2 2017
Type 2 Diabetes - Pipeline by Cardax Inc, H2 2017
Type 2 Diabetes - Pipeline by Carmot Therapeutics Inc, H2 2017
Type 2 Diabetes - Pipeline by Celon Pharma SA, H2 2017
Type 2 Diabetes - Pipeline by Center Laboratories Inc, H2 2017
Type 2 Diabetes - Pipeline by Chipscreen Biosciences Ltd, H2 2017
Type 2 Diabetes - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
Type 2 Diabetes - Pipeline by CJ HealthCare Corp, H2 2017
Type 2 Diabetes - Pipeline by CohBar Inc, H2 2017
Type 2 Diabetes - Pipeline by Concenter BioPharma Silkim Ltd, H2 2017
Type 2 Diabetes - Pipeline by Connexios Life Sciences Pvt Ltd, H2 2017
Type 2 Diabetes - Pipeline by ConSynance Therapeutics Inc, H2 2017
Type 2 Diabetes - Pipeline by CSL Ltd, H2 2017
Type 2 Diabetes - Pipeline by CureDM Inc, H2 2017
Type 2 Diabetes - Pipeline by CymaBay Therapeutics Inc, H2 2017
Type 2 Diabetes - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Dance Biopharm Inc, H2 2017
Type 2 Diabetes - Pipeline by Delpor Inc, H2 2017
Type 2 Diabetes - Pipeline by Diabetology (Products) Ltd, H2 2017
Type 2 Diabetes - Pipeline by DiaMedica Therapeutics Inc, H2 2017
Type 2 Diabetes - Pipeline by Diamyd Medical AB, H2 2017
Type 2 Diabetes - Pipeline by Diasome Pharmaceuticals Inc, H2 2017
Type 2 Diabetes - Pipeline by DiscoveryBiomed Inc, H2 2017
Type 2 Diabetes - Pipeline by DNJ Pharma Inc, H2 2017
Type 2 Diabetes - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Elcelyx Therapeutics Inc, H2 2017
Type 2 Diabetes - Pipeline by Eli Lilly and Co, H2 2017
Type 2 Diabetes - Pipeline by Energenesis Biomedical Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Enteris BioPharma Inc, H2 2017
Type 2 Diabetes - Pipeline by Enzene Biosciences Ltd, H2 2017
Type 2 Diabetes - Pipeline by Enzo Biochem Inc, H2 2017
Type 2 Diabetes - Pipeline by Epichem Pty Ltd, H2 2017
Type 2 Diabetes - Pipeline by Eternygen GmbH, H2 2017
Type 2 Diabetes - Pipeline by Evotec AG, H2 2017
Type 2 Diabetes - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Type 2 Diabetes - Pipeline by Genexine Inc, H2 2017
Type 2 Diabetes - Pipeline by Genfit SA, H2 2017
Type 2 Diabetes - Pipeline by Genmedica Therapeutics SL, H2 2017
Type 2 Diabetes - Pipeline by Genovate Biotechnology Co LTD, H2 2017
Type 2 Diabetes - Pipeline by Geropharm LLC, H2 2017
Type 2 Diabetes - Pipeline by Gilead Sciences Inc, H2 2017
Type 2 Diabetes - Pipeline by GlaxoSmithKline Plc, H2 2017
Type 2 Diabetes - Pipeline by Glucox Biotech AB, H2 2017
Type 2 Diabetes - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Heptares Therapeutics Ltd, H2 2017
Type 2 Diabetes - Pipeline by HitGen LTD, H2 2017
Type 2 Diabetes - Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Immuron Ltd, H2 2017
Type 2 Diabetes - Pipeline by Inflazome Ltd, H2 2017
Type 2 Diabetes - Pipeline by Innovative Targeting Solutions Inc, H2 2017
Type 2 Diabetes - Pipeline by Inspyr Therapeutics Inc, H2 2017
Type 2 Diabetes - Pipeline by InStar Technologies AS, H2 2017
Type 2 Diabetes - Pipeline by Intarcia Therapeutics Inc, H2 2017
Type 2 Diabetes - Pipeline by Intas Pharmaceuticals Ltd, H2 2017
Type 2 Diabetes - Pipeline by Integral Molecular Inc, H2 2017
Type 2 Diabetes - Pipeline by Intercept Pharmaceuticals Inc, H2 2017
Type 2 Diabetes - Pipeline by Intrexon Corp, H2 2017
Type 2 Diabetes - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Type 2 Diabetes - Pipeline by Islet Sciences Inc, H2 2017
Type 2 Diabetes - Pipeline by Japan Tobacco Inc, H2 2017
Type 2 Diabetes - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by JHL Biotech Inc, H2 2017
Type 2 Diabetes - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Johnson & Johnson, H2 2017
Type 2 Diabetes - Pipeline by Kadimastem Ltd, H2 2017
Type 2 Diabetes - Pipeline by Kadmon Corp LLC, H2 2017
Type 2 Diabetes - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Kowa Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Lead Discovery Center GmbH, H2 2017
Type 2 Diabetes - Pipeline by Leading BioSciences Inc, H2 2017
Type 2 Diabetes - Pipeline by Lexicon Pharmaceuticals Inc, H2 2017
Type 2 Diabetes - Pipeline by LG Chem Ltd, H2 2017
Type 2 Diabetes - Pipeline by Ligand Pharmaceuticals Inc, H2 2017
Type 2 Diabetes - Pipeline by LipimetiX Development Inc, H2 2017
Type 2 Diabetes - Pipeline by Longevity Biotech Inc, H2 2017
Type 2 Diabetes - Pipeline by Luye Pharma Group Ltd, H2 2017
Type 2 Diabetes - Pipeline by Magnus Life Ltd, H2 2017
Type 2 Diabetes - Pipeline by MannKind Corp, H2 2017
Type 2 Diabetes - Pipeline by Medesis Pharma SA, H2 2017
Type 2 Diabetes - Pipeline by Medestea Research & Production SpA, H2 2017
Type 2 Diabetes - Pipeline by MedImmune LLC, H2 2017
Type 2 Diabetes - Pipeline by Medlab Clinical Ltd, H2 2017
Type 2 Diabetes - Pipeline by Melior Discovery Inc, H2 2017
Type 2 Diabetes - Pipeline by Mellitech SAS, H2 2017
Type 2 Diabetes - Pipeline by Merck & Co Inc, H2 2017
Type 2 Diabetes - Pipeline by Mesoblast Ltd, H2 2017
Type 2 Diabetes - Pipeline by Metabolic Solutions Development Company LLC, H2 2017
Type 2 Diabetes - Pipeline by Metabolys SAS, H2 2017
Type 2 Diabetes - Pipeline by Metacrine Inc, H2 2017
Type 2 Diabetes - Pipeline by Mitsubishi Chemical Holdings Corp, H2 2017
Type 2 Diabetes - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
Type 2 Diabetes - Pipeline by Naia Ltd, H2 2017
Type 2 Diabetes - Pipeline by Neurimmune Holding AG, H2 2017
Type 2 Diabetes - Pipeline by Neurocrine Biosciences Inc, H2 2017
Type 2 Diabetes - Pipeline by NGM Biopharmaceuticals Inc, H2 2017
Type 2 Diabetes - Pipeline by Nordic Bioscience A/S, H2 2017
Type 2 Diabetes - Pipeline by Novapeutics LLC, H2 2017
Type 2 Diabetes - Pipeline by Novartis AG, H2 2017
Type 2 Diabetes - Pipeline by NovaTarg Therapeutics Inc, H2 2017
Type 2 Diabetes - Pipeline by Novo Nordisk AS, H2 2017
Type 2 Diabetes - Pipeline by Omeros Corp, H2 2017
Type 2 Diabetes - Pipeline by OPKO Biologics Ltd, H2 2017
Type 2 Diabetes - Pipeline by OPKO Health Inc, H2 2017
Type 2 Diabetes - Pipeline by Oramed Pharmaceuticals Inc, H2 2017
Type 2 Diabetes - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2017
Type 2 Diabetes - Pipeline by Peptron Inc, H2 2017
Type 2 Diabetes - Pipeline by Pfizer Inc, H2 2017
Type 2 Diabetes - Pipeline by PharmaCyte Biotech Inc, H2 2017
Type 2 Diabetes - Pipeline by PharmaIN Corp, H2 2017
Type 2 Diabetes - Pipeline by Pila Pharma AB, H2 2017
Type 2 Diabetes - Pipeline by Poxel SA, H2 2017
Type 2 Diabetes - Pipeline by Prometheon Pharma LLC, H2 2017
Type 2 Diabetes - Pipeline by ProMetic Life Sciences Inc, H2 2017
Type 2 Diabetes - Pipeline by Prothena Corp Plc, H2 2017
Type 2 Diabetes - Pipeline by Purzer Pharmaceutical Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Reata Pharmaceuticals Inc, H2 2017
Type 2 Diabetes - Pipeline by ReCyte Therapeutics Inc, H2 2017
Type 2 Diabetes - Pipeline by reMYND NV, H2 2017
Type 2 Diabetes - Pipeline by Renova Therapeutics Inc, H2 2017
Type 2 Diabetes - Pipeline by Reset Therapeutics Inc, H2 2017
Type 2 Diabetes - Pipeline by Saniona AB, H2 2017
Type 2 Diabetes - Pipeline by Sanofi, H2 2017
Type 2 Diabetes - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by SATT Conectus Alsace SAS, H2 2017
Type 2 Diabetes - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Seres Therapeutics Inc, H2 2017
Type 2 Diabetes - Pipeline by Serodus ASA, H2 2017
Type 2 Diabetes - Pipeline by Serometrix LLC, H2 2017
Type 2 Diabetes - Pipeline by Sevion Therapeutics Inc, H2 2017
Type 2 Diabetes - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H2 2017
Type 2 Diabetes - Pipeline by Shionogi & Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Sirona Biochem Corp, H2 2017
Type 2 Diabetes - Pipeline by SJT Molecular Research SL, H2 2017
Type 2 Diabetes - Pipeline by SK Chemicals Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Sprint Bioscience AB, H2 2017
Type 2 Diabetes - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Suzuken Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Teijin Pharma Ltd, H2 2017
Type 2 Diabetes - Pipeline by The Medicines Company, H2 2017
Type 2 Diabetes - Pipeline by Theracos Inc, H2 2017
Type 2 Diabetes - Pipeline by Thermalin Diabetes LLC, H2 2017
Type 2 Diabetes - Pipeline by Tiziana Life Sciences Plc, H2 2017
Type 2 Diabetes - Pipeline by Toray Industries Inc, H2 2017
Type 2 Diabetes - Pipeline by Torrent Pharmaceuticals Ltd, H2 2017
Type 2 Diabetes - Pipeline by Transgene Biotek Ltd, H2 2017
Type 2 Diabetes - Pipeline by TTY Biopharm Company Ltd, H2 2017
Type 2 Diabetes - Pipeline by Twoxar Inc, H2 2017
Type 2 Diabetes - Pipeline by Uni-Bio Science Group Ltd, H2 2017
Type 2 Diabetes - Pipeline by ViaCyte Inc, H2 2017
Type 2 Diabetes - Pipeline by Vichem Chemie Research Ltd, H2 2017
Type 2 Diabetes - Pipeline by Vicore Pharma AB, H2 2017
Type 2 Diabetes - Pipeline by Viking Therapeutics Inc, H2 2017
Type 2 Diabetes - Pipeline by Vivus Inc, H2 2017
Type 2 Diabetes - Pipeline by vTv Therapeutics Inc, H2 2017
Type 2 Diabetes - Pipeline by Vybion Inc, H2 2017
Type 2 Diabetes - Pipeline by XBiotech Inc, H2 2017
Type 2 Diabetes - Pipeline by XL-protein GmbH, H2 2017
Type 2 Diabetes - Pipeline by XOMA Corp, H2 2017
Type 2 Diabetes - Pipeline by XuanZhu Pharma Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Yabao Pharmaceutical Group Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Yuhan Corp, H2 2017
Type 2 Diabetes - Pipeline by Yungjin Pharm Co Ltd, H2 2017
Type 2 Diabetes - Pipeline by Zafgen Inc, H2 2017
Type 2 Diabetes - Pipeline by Zealand Pharma AS, H2 2017
Type 2 Diabetes - Dormant Projects, H2 2017 1073
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..1), H2 2017 1074
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..2), H2 2017 1075
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..3), H2 2017 1076
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..4), H2 2017 1077
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..5), H2 2017 1078
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..6), H2 2017 1079
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..7), H2 2017 1080
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..8), H2 2017 1081
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..9), H2 2017 1082
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..10), H2 2017 1083
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..11), H2 2017 1084
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..12), H2 2017 1085
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..13), H2 2017 1086
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..14), H2 2017 1087
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..15), H2 2017 1088
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..16), H2 2017 1089
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..17), H2 2017 1090
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..18), H2 2017 1091
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..19), H2 2017 1092
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..20), H2 2017 1093
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..21), H2 2017 1094
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..22), H2 2017 1095
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..23), H2 2017 1096
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..24), H2 2017 1097
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..25), H2 2017 1099
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..26), H2 2017 1100
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..27), H2 2017 1101
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..28), H2 2017 1102
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..29), H2 2017 1103
Type 2 Diabetes - Dormant Projects, H2 2017 (Contd..30), H2 2017 1104
Type 2 Diabetes - Discontinued Products, H2 2017 1105
Type 2 Diabetes - Discontinued Products, H2 2017 (Contd..1), H2 2017 1106
Type 2 Diabetes - Discontinued Products, H2 2017 (Contd..2), H2 2017 1107
Type 2 Diabetes - Discontinued Products, H2 2017 (Contd..3), H2 2017 1108
Type 2 Diabetes - Discontinued Products, H2 2017 (Contd..4), H2 2017 1109
Type 2 Diabetes - Discontinued Products, H2 2017 (Contd..5), H2 2017 1110
Type 2 Diabetes - Discontinued Products, H2 2017 (Contd..6), H2 2017 1111
Type 2 Diabetes - Discontinued Products, H2 2017 (Contd..7), H2 2017 1112
Type 2 Diabetes - Discontinued Products, H2 2017 (Contd..8), H2 2017 1113
Type 2 Diabetes - Discontinued Products, H2 2017 (Contd..9), H2 2017 1114

LIST OF FIGURES

Number of Products under Development for Type 2 Diabetes, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

4P Therapeutics LLC
Addex Therapeutics Ltd
Adocia SAS
Aegis Therapeutics LLC
AFFiRiS AG
Allergan Plc
Amarantus Bioscience Holdings Inc
Amgen Inc
AntriaBio Inc
Aphios Corp
Araim Pharmaceuticals Inc
Arecor Ltd
Arena Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
AusBio Ltd
Avadel Pharmaceuticals Plc
Bayer AG
Betagenon AB
Betta Pharmaceuticals Co Ltd
Biocon Ltd
BioLingus AG
BioRestorative Therapies Inc
Biozeus
Biscayne Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Boston Therapeutics Inc
Braasch Biotech LLC
Bristol-Myers Squibb Co
C4X Discovery Holdings PLC
Cadila Healthcare Ltd
Cadila Pharmaceuticals Ltd
Caelus Health
Cardax Inc
Carmot Therapeutics Inc
Celon Pharma SA
Center Laboratories Inc
Chipscreen Biosciences Ltd
Chong Kun Dang Pharmaceutical Corp
CJ HealthCare Corp
CohBar Inc
Concenter BioPharma Silkim Ltd
Connexios Life Sciences Pvt Ltd
ConSynance Therapeutics Inc
CSL Ltd
CureDM Inc
CymaBay Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Dance Biopharm Inc
Delpor Inc
Diabetology (Products) Ltd
DiaMedica Therapeutics Inc
Diamyd Medical AB
Diasome Pharmaceuticals Inc
DiscoveryBiomed Inc
DNJ Pharma Inc
Dong-A Socio Holdings Co Ltd
Elcelyx Therapeutics Inc
Eli Lilly and Co
Energenesis Biomedical Co Ltd
Enteris BioPharma Inc
Enzene Biosciences Ltd
Enzo Biochem Inc
Epichem Pty Ltd
Eternygen GmbH
Evotec AG
F. Hoffmann-La Roche Ltd
Genexine Inc
Genfit SA
Genmedica Therapeutics SL
Genovate Biotechnology Co LTD
Geropharm LLC
Gilead Sciences Inc
GlaxoSmithKline Plc
Glucox Biotech AB
Hanmi Pharmaceuticals Co Ltd
Heptares Therapeutics Ltd
HitGen LTD
Hyundai Pharmaceutical Co Ltd
Immuron Ltd
Inflazome Ltd
Innovative Targeting Solutions Inc
Inspyr Therapeutics Inc
InStar Technologies AS
Intarcia Therapeutics Inc
Intas Pharmaceuticals Ltd
Integral Molecular Inc
Intercept Pharmaceuticals Inc
Intrexon Corp
Ionis Pharmaceuticals Inc
Islet Sciences Inc
Japan Tobacco Inc
Jeil Pharmaceutical Co Ltd
JHL Biotech Inc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kadimastem Ltd
Kadmon Corp LLC
Kissei Pharmaceutical Co Ltd
Kowa Co Ltd
Lead Discovery Center GmbH
Leading BioSciences Inc
Lexicon Pharmaceuticals Inc
LG Chem Ltd
Ligand Pharmaceuticals Inc
LipimetiX Development Inc
Longevity Biotech Inc
Luye Pharma Group Ltd
Magnus Life Ltd
MannKind Corp
Medesis Pharma SA
Medestea Research & Production SpA
MedImmune LLC
Medlab Clinical Ltd
Melior Discovery Inc
Mellitech SAS
Merck & Co Inc
Mesoblast Ltd
Metabolic Solutions Development Company LLC
Metabolys SAS
Metacrine Inc
Mitsubishi Chemical Holdings Corp
Mitsubishi Tanabe Pharma Corp
Naia Ltd
Neurimmune Holding AG
Neurocrine Biosciences Inc
NGM Biopharmaceuticals Inc
Nordic Bioscience A/S
Novapeutics LLC
Novartis AG
NovaTarg Therapeutics Inc
Novo Nordisk AS
Omeros Corp
OPKO Biologics Ltd
OPKO Health Inc
Oramed Pharmaceuticals Inc
Paras Biopharmaceuticals Finland Oy
Peptron Inc
Pfizer Inc
PharmaCyte Biotech Inc
PharmaIN Corp
Pila Pharma AB
Poxel SA
Prometheon Pharma LLC
ProMetic Life Sciences Inc
Prothena Corp Plc
Purzer Pharmaceutical Co Ltd
Reata Pharmaceuticals Inc
ReCyte Therapeutics Inc
reMYND NV
Renova Therapeutics Inc
Reset Therapeutics Inc
Saniona AB
Sanofi
Sanwa Kagaku Kenkyusho Co Ltd
SATT Conectus Alsace SAS
SBI Pharmaceuticals Co Ltd
Seres Therapeutics Inc
Serodus ASA
Serometrix LLC
Sevion Therapeutics Inc
Shenzhen HighTide Biopharmaceutical Ltd
Shionogi & Co Ltd
Sirona Biochem Corp
SJT Molecular Research SL
SK Chemicals Co Ltd
Sprint Bioscience AB
Sumitomo Dainippon Pharma Co Ltd
Suzuken Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Tasly Pharmaceutical Group Co Ltd
Teijin Pharma Ltd
The Medicines Company
Theracos Inc
Thermalin Diabetes LLC
Tiziana Life Sciences Plc
Toray Industries Inc
Torrent Pharmaceuticals Ltd
Transgene Biotek Ltd
TTY Biopharm Company Ltd
Twoxar Inc
Uni-Bio Science Group Ltd
ViaCyte Inc
Vichem Chemie Research Ltd
Vicore Pharma AB
Viking Therapeutics Inc
Vivus Inc
vTv Therapeutics Inc
Vybion Inc
XBiotech Inc
XL-protein GmbH
XOMA Corp
XuanZhu Pharma Co Ltd
Yabao Pharmaceutical Group Co Ltd
Yuhan Corp
Yungjin Pharm Co Ltd
Zafgen Inc
Zealand Pharma AS
Skip to top


Ask Your Question

Type 2 Diabetes - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: